{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Non-small+Cell+Lung+Cancer+%28NSCLC%29&page=27", "query": { "condition": "Advanced Non-small Cell Lung Cancer (NSCLC)", "page": 27 }, "page_size": 10 }, "pagination": { "page": 27, "page_size": 10, "total_count": 1796, "total_pages": 180, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Non-small+Cell+Lung+Cancer+%28NSCLC%29&page=28&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Non-small+Cell+Lung+Cancer+%28NSCLC%29&page=26&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T00:53:48.544Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00986674", "title": "Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Non-small Cell Lung Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Non-small Cell Lung Cancer" ], "interventions": [ { "name": "cixutumumab", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "cetuximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2009-09", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2014-09-26", "last_synced_at": "2026-10-15T00:53:48.544Z", "location_count": 249, "location_summary": "Stanford, California • Aurora, Colorado • Boulder, Colorado + 171 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00986674" }, { "nct_id": "NCT07154290", "title": "A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Advanced Non Small Cell Lung Cancer", "Metastatic Non Small Cell Lung Cancer", "Carcinoma Non Small Cell Lung" ], "interventions": [ { "name": "Ubamatamab", "type": "DRUG" }, { "name": "Marlotamig", "type": "DRUG" }, { "name": "Sarilumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2026-03-18", "completion_date": "2030-06-10", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-15T00:53:48.544Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Irvine, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07154290" }, { "nct_id": "NCT00517790", "title": "Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "ABT-869 .25 mg/kg", "type": "DRUG" }, { "name": "ABT-869 0.10 mg/kg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2007-08", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2013-04-05", "last_synced_at": "2026-10-15T00:53:48.544Z", "location_count": 18, "location_summary": "Fountain Valley, California • Los Angeles, California • Sacramento, California + 15 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Waterbury", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00517790" }, { "nct_id": "NCT03957096", "title": "A Safety Study of SGN-CD47M in Patients With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Soft Tissue Sarcoma", "Colorectal Cancer", "Head and Neck Squamous Cell Carcinoma", "Non-small Cell Lung Carcinoma", "Breast Carcinoma", "Ovarian Carcinoma", "Exocrine Pancreatic Carcinoma", "Gastric Carcinoma", "Melanoma" ], "interventions": [ { "name": "SGN-CD47M", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2019-07-17", "completion_date": "2020-09-14", "has_results": false, "last_update_posted_date": "2020-09-17", "last_synced_at": "2026-10-15T00:53:48.544Z", "location_count": 5, "location_summary": "Cleveland, Ohio • Portland, Oregon • Nashville, Tennessee + 2 more", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03957096" }, { "nct_id": "NCT00246727", "title": "Effects of Selected Vegetable and Herb Mix (SV) on Advanced Non-small Cell Lung Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Selected Vegetable and Herb Mix", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sun Farm Corporation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2005-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-10-31", "last_synced_at": "2026-10-15T00:53:48.544Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00246727" }, { "nct_id": "NCT07064018", "title": "Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Soft-tissue Sarcoma", "Triple Negative Breast Cancer", "Non-small Cell Lung Cancer", "Cervical Cancer", "Ovarian Cancer", "KRAS Mutation-Related Tumors" ], "interventions": [ { "name": "Spedox-6", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2025-04-30", "completion_date": "2031-12-31", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-15T00:53:48.544Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07064018" }, { "nct_id": "NCT06579196", "title": "Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Trabedersen", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 45, "start_date": "2025-05-12", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-15T00:53:48.544Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06579196" }, { "nct_id": "NCT03037385", "title": "Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "RET-altered Non Small Cell Lung Cancer", "Medullary Thyroid Cancer", "RET-altered Papillary Thyroid Cancer", "RET-altered Colon Cancer", "RET-altered Solid Tumors", "Lung Neoplasm", "Carcinoma, Non-Small-Cell Lung", "Thyroid Diseases", "Thyroid Neoplasm", "Thyroid Cancer, Papillary", "Carcinoma, Neuroendocrine", "Respiratory Tract Neoplasms", "Thoracic Neoplasms", "Neoplasms by Site", "Neoplasms", "Lung Diseases", "Respiratory Tract Disease", "Carcinoma, Bronchogenic", "Bronchial Neoplasms", "Endocrine System Diseases", "Endocrine Gland Neoplasm", "Head and Neck Neoplasms", "Adenocarcinoma, Papillary", "Adenocarcinoma", "Carcinoma", "Neoplasms, Glandular and Epithelial", "Neoplasms by Histologic Type", "Neuroendocrine Tumors", "Neuroectodermal Tumors", "Neoplasms, Germ Cell and Embryonal", "Neoplasms, Nerve Tissue", "Colonic Neoplasms", "Colorectal Neoplasms", "Intestinal Neoplasms", "Gastrointestinal Neoplasms", "Digestive System Neoplasm", "Digestive System Disease", "Gastrointestinal Disease", "Colonic Diseases", "Intestinal Disease" ], "interventions": [ { "name": "pralsetinib (BLU-667)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 590, "start_date": "2017-03-17", "completion_date": "2024-03-21", "has_results": true, "last_update_posted_date": "2025-05-31", "last_synced_at": "2026-10-15T00:53:48.544Z", "location_count": 18, "location_summary": "Phoenix, Arizona • Orange, California • Aurora, Colorado + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03037385" }, { "nct_id": "NCT03329950", "title": "A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Non-small Cell Lung Cancer", "Breast Cancer", "Gastric Cancer", "Renal Cell Carcinoma", "Ovarian Cancer", "Cholangiocarcinoma", "Bladder Urothelial Carcinoma", "Pancreatic Adenocarcinoma", "Colorectal Cancer", "Esophageal Cancer", "Hepatic Cancer", "Head and Neck Cancer", "Primary Peritoneal Cancer", "Fallopian Tube Cancer", "Other Solid Tumors", "Diffuse Large B-cell Lymphoma (DLBCL)", "Mantle Cell Lymphoma", "Indolent B-cell Lymphomas", "Non-Hodgkin Lymphoma", "Follicular Lymphoma", "Lymphoplasmacytic Lymphoma", "Waldenstrom's Disease", "Marginal Zone Lymphoma", "Mucosa Associated Lymphoid Tissue", "Small Lymphocytic Leukemia" ], "interventions": [ { "name": "CDX-1140", "type": "DRUG" }, { "name": "CDX-301", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2017-12-01", "completion_date": "2022-09-13", "has_results": false, "last_update_posted_date": "2024-03-28", "last_synced_at": "2026-10-15T00:53:48.544Z", "location_count": 11, "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Augusta, Georgia + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03329950" }, { "nct_id": "NCT03023423", "title": "A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2016-12-23", "completion_date": "2019-09-26", "has_results": true, "last_update_posted_date": "2019-11-20", "last_synced_at": "2026-10-15T00:53:48.544Z", "location_count": 16, "location_summary": "Loma Linda, California • Whittier, California • Newark, Delaware + 13 more", "locations": [ { "city": "Loma Linda", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03023423" } ] }